2006 Drugs Pharmaceuticals 
Drug Target Review
JUNE 6, 2025
Image credit: Crystal Eye Media / Shutterstock The role of SPICA and manufacturing capabilities Drug development in the radiopharmaceutical space is particularly resource intensive. Shared goals in cancer drug discovery For all its internal capabilities, RMX does not operate in isolation. This is where the SPICA Center comes in.
Drug Target Review
JUNE 2, 2025
Bioconjugates are rapidly emerging as a key frontier in targeted therapies, particularly through Antibody-Drug Conjugates (ADCs) , which combine antibodies with cytotoxic drugs to deliver more precise and effective treatments. The addition of Drug Product assets for cytotoxic substances completes the fully integrated offering.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Alta Sciences
MARCH 4, 2025
The CCALC is a grassroots organization that was founded by several pharmaceutical industry members seeking clarity around the conduct of abuse and dependence potential assessments for novel drugs in development. This was in 2006, at a time when the FDA guidances on these topics had not yet been published.
New Drug Approvals
JUNE 11, 2025
2] Gepirone was synthesized by Bristol-Myers Squibb in 1986 and was developed and marketed by Fabre-Kramer Pharmaceuticals. [4] 4] This came after the drug had been rejected by the Food and Drug Administration (FDA) three times over two decades due to insufficient evidence of effectiveness. [5] Food and Drug Administration.
New Drug Approvals
APRIL 25, 2025
12] However, absorption, metabolism, and excretion data of taselisib , a molecule with a related chemical scaffold, suggest moderately slow absorption into the systemic circulation, metabolism to play a minor role in drug clearance, and biliary excretion to be the main route of excretion. [13] 3 November 2006. 3 November 2006.
Drug Channels
DECEMBER 12, 2024
This week, Im rerunning some popular posts while I prepare for tomorrows Drug Channels Outlook 2025 live video webinar. Time for DCIs annual update on the channels for provider-administered drugs. drug channels. Read more 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.
Drug Patent Watch
JANUARY 13, 2025
The Rise of Biosimilars: A Healthcare Revolution Biosimilars, often referred to as the “generic equivalents” of biologic drugs, have been making waves in the pharmaceutical industry for over a decade. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4
Expert insights. Personalized for you.
100 
Let's personalize your content